Am J Transplant, Volume 16, Suppl 3 Archives - Page 45 of 180 - ATC Abstracts

2016 American Transplant Congress
Expansion of Regulatory B-Cells and Their Potential Role in Transplantation Tolerance.
B. Amundsen, H. Deirawan, J. Kim, J. Markmann.
Massachusetts General Hospital, Boston, MA.
IntroductionRegulatory B (Bregs) cells, B cells which produce IL-10, have been shown to play a critical role in immune homeostasis and autoimmunity models. Despite the…
2016 American Transplant Congress
Role of NRP1 in CD4+ T Cell Allo-Activation.
E. Lee, H. Kim, G. Demirci.
Department of Surgery, Boston Children's Hospital, Boston, MA.
Introduction: Neuropilin-1 (NRP1) is a transmembrane glycoprotein that functions as a co-receptor for class III/IV semaphorins, VEGF, and several other growth factors. NRP1 has been…
2016 American Transplant Congress
Better Long-Term Renal Function with Lower Incidence of Acute Rejection and Lower CMV Infection in Renal Transplant Patients Treated with a Combination of Tacrolimus and Everolimus.
G. Spagnoletti, M. Salerno, V. Bianchi, N. Silvestrini, F. Apponi, J. Romagnoli, F. Citterio.
Surgery - Renal Transplant Unit, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction. Recent clinical trials have shown that the combination of CNIs with Everolimus (EVE) allows CNIs minimization, which may positively impact on chronic nephrotoxicity. Aim…
2016 American Transplant Congress
Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States: Epidemiology, Outcomes, and Costs.
A. Mathur, Y.-H. Chang, D. Steidley, N. Khurmi, N. Katariya, A. Singer, W. Hewitt, K. Reddy, A. Moss.
Transplant Center, Mayo Clinic, Phoenix.
Background: Cardiovascular disease (CVD) is a leading cause of post-liver transplant death, and variable care patterns may affect outcomes. We aimed to describe epidemiology, outcomes,…
2016 American Transplant Congress
Glycine Is Graft Protective and Improves Kidney Function After Liver Transplantation: Data from HEGPOL-Trial.
A. Nickkholgh,¹ P. Schemmer,¹ G. Polychronidis,¹ S. Luntz,² E. Mayatepek,³ M. Büchler,¹ E. Klar.⁴
¹General, Abdominal and Transplant Surgery, Ruprecht-Karls University, Heidelberg, BW, Germany; ²Coordination Center for Clinical Trials (KKS), Heidelberg, BW, Germany; ³Department of General Pediatrics, Heinrich-Heine-University, Düsseldorf, RP, Germany; ⁴Department of Surgery, University of Rostock, Rostock, Germany.
Introduction: In experimental liver transplantation (LTx), glycine, a non-essential amino acid, has been shown to prevent the activation of Kupffer cells and to reduce ischemia/reperfusion…
2016 American Transplant Congress
Everolimus versus Mycophenolate Mofetil in Combination with Tacrolimus: A Propensity Score Matching Analysis in Liver Transplantation.
P. de Simone,¹ P. Carrai,¹ A. Precisi,² L. Coletti,¹ D. Ghinolfi,¹ F. Filipponi.¹
¹Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospitals, Pisa, Italy; ²Laboratory, University of Pisa Medical School Hospital, Pisa, Italy.
Background: No trial has so far investigated everolimus (EVR)-incorporating immunosuppressive regimens versus combined use of tacrolimus (TAC) and mycophenolate mofetil (MMF) in liver transplantation (LT).Materials…
2016 American Transplant Congress
African-American Primary Renal Transplant Recipients Are at a Significantly Higher Risk to Develop De Novo DSA.
M. Everly,¹ L. Rebellato,² C. Haisch,² K. Briley,² P. Bolin,² S. Kendrick,³ C. Morgan,² A. Maldonado,⁴ A. Nguyen,¹ P. Terasaki.¹
¹Terasaki Foundation Laboratory, Los Angeles; ²East Carolina University, Greenville, NC; ³Eastern Nephrology Associates, Greenville, NC; ⁴Vidant Medical Center, Greenville, NC.
Recent studies have shown multiple risk factors for de novo DSA (dnDSA) development. One controversial risk factor is race. Studying a primarily African-American (AA) transplant…
2016 American Transplant Congress
Kidney Retransplantation Is Associated with Higher Mortality Risk Among HIV+ vs. HIV- Recipients.
B. Shelton,¹ S. Mehta,¹ D. Sawinski,² R. Reed,¹ P. MacLennan,¹ S. Gustafson,³ C. Durand,⁴ D. Segev,⁴ J. Locke.¹
¹School of Medicine, University of Alabama at Birmingham, Birmingham, AL; ²School of Medicine, University of Pennsylvania, Philadelphia, PA; ³Scientific Registry of Transplant Recipients, Minneapolis, MN; ⁴School of Medicine, Johns Hopkins University, Baltimore, MD.
Background: Excellent outcomes have been demonstrated in HIV+ kidney transplant (KT) recipients, yet no study has explored outcomes among HIV+ reKT recipients.Methods: 4,683 adult reKT…
2016 American Transplant Congress
Modification of DC Phenotype and Function via Targeted Porous Silicon Nanoparticles.
S. Stead,¹ S. McInnes,² S. Kireta,³ P. Rose,¹ D. Rojas-Canales,³ S. Jesudason,³ S. Grey,⁴ R. Carroll,³ N. Voelcker,² P. Coates.^1,3
¹School of Medicine, University of Adelaide, Adelaide, Australia; ²Future Industries Institute, University of South Australia, Adelaide, Australia; ³CNARTS, Royal Adelaide Hospital, Adealide, Australia; ⁴Transplantation Immunology, Garvan Institute of Medical Research, Sydney, Australia.
Aims: Dendritic cells (DC) are the most potent antigen-presenting cell and are fundamental in the establishment of transplant tolerance. Targeting DC via the DC-SIGN receptor…
2016 American Transplant Congress
Three-Year Graft Loss Risk in Kidney Transplants: Dynamic Patient Level Data Improve Predictive Efficacy.
T. Srinivas, J. Zhang, Z. Su, D. Taber, J. Marsden, K. Reilly, D. Northrup, J. Long, L. Lenert, W. Moran, P. Mauldin.
MUSC, Charleston, SC.
Background: Predictive models in kidney transplantation using national data (UNOS, SRTR) lack longitudinal patient level data, limiting accuracy. Adding patient level data capturing dynamic clinical…